Multi-CRO trials force a question that single-CRO trials can avoid: who owns the canonical subject identity? A sponsor-hosted MPI gives the sponsor full control; a federated eMPI distributes the ownership across CROs and sites. Both archite

Identifier collisions happen quietly in multi-site trials. Site A starts numbering subjects at 001 in its local EDC; Site B starts at the same number; the sponsor's MPI pulls both into a single identifier slot and treats them as the same su

Decentralized trials change the shape of subject reconciliation in ways that catch sponsors off guard. Subjects enroll through self-service flows, lose their identifiers, switch devices, and sometimes try to enroll twice. The MPI has to han

Open-source MPI solutions are a real path for clinical research networks that want full control over the identity layer. The trade-off (engineering ownership in exchange for licensing savings) cuts differently in research than in routine he

Deterministic and probabilistic subject matching are not interchangeable, even though most procurement documents treat them as a single check box. Each works well in a different part of the trial lifecycle, and the right MPI uses both. Here

Subject reconciliation on the sponsor side is the work of taking subject records from many sources (sites, ePRO platforms, labs, imaging vendors) and producing one canonical identity per subject in the sponsor's environment. Done well, it i

Reconciling subject records across investigator sites is where matching algorithms earn their keep. The data is dirtier than the demos suggest, the rules of thumb that work in hospital MPI work less well in trials, and the cost of a bad mat

Multi-site trial networks live or die on whether the same subject can be recognized cleanly across sites, sponsors, and CROs. The FHIR-native MPI tools that actually deliver on that bar are a short list. Here are the five worth a real evalu